Table 5.
The effect of clinical and sociodemographic factors on lead times in care process for the 845 patients in the Stockholm region diagnosed with high grade glioma 2001–2013
| Negative binomial regression | From diagnosis to surgery (univariate) | From diagnosis to surgery (multivariate) | From surgery to start of non-surgical cancer treatment (univariate) | From surgery to start of non-surgical cancer treatment (multivariate) | ||||
|---|---|---|---|---|---|---|---|---|
| IRR (CI) | p value | IRR (CI) | p value | IRR (CI) | p value | IRR (CI) | p value | |
| Age category (ref: 18–39) | ||||||||
| 40–59 | 0.59 (0.44–0.81) | 0.001 | 1.13 (0.82–1.55) | 0.455 | 0.42 (0.33–0.52) | 0.000 | 0.67 (0.53–0.86) | 0.002 |
| 60–69 | 0.55 (0.40–0.75) | 0.000 | 1.30 (0.94–1.82) | 0.117 | 0.40 (0.32–0.50) | 0.000 | 0.68 (0.52–0.87) | 0.003 |
| 70– | 0.82 (0.57–1.20) | 0.306 | 1.64 (1.10–2.45) | 0.015 | 0.73 (0.52–1.02) | 0.063 | 1.21 (0.84–1.75) | 0.306 |
| Year of diagnosis (ref: 01/04) | ||||||||
| 05/07 | 1.57 (1.03–2.38) | 0.035 | 0.91 (0.61–1.35) | 0.635 | 0.43 (0.29–0.62) | 0.000 | 0.64 (0.42–0.98) | 0.038 |
| 08/10 | 1.40 (0.93–2.10) | 0.105 | 1.36 (0.92–2.01) | 0.127 | 0.26 (0.18–0.37) | 0.000 | 0.42 (0.27–0.63) | 0.000 |
| 11/13 | 0.91 (0.61–1.37) | 0.651 | 0.97 (0.65–1.43) | 0.870 | 0.29 (0.20–0.42) | 0.000 | 0.40 (0.26–0.61) | 0.000 |
| Sex | ||||||||
| Male | 0.83 (0.69-1.00) | 0.049 | 0.91 (0.76–1.08) | 0.286 | 1.25 (1.08–1.46) | 0.003 | 1.01 (0.87–1.18) | 0.863 |
| Comorbidity* | 1.57 (1.31–1.89) | 0.000 | 1.53 (1.28–1.83) | 0.000 | 0.81 (0.70–0.95) | 0.010 | 0.94 (0.81–1.10) | 0.460 |
| Educational level (ref: elementary) | ||||||||
| High school diploma | 1.00 (0.78–1.29) | 0.997 | 1.11 (0.87–1.41) | 0.409 | 1.19 (0.96–1.48) | 0.114 | 1.06 (0.86–1.31) | 0.588 |
| University degree | 0.74 (0.57–0.95) | 0.018 | 1.02 (0.79–1.31) | 0.879 | 1.32 (1.07–1.64) | 0.011 | 0.98 (0.78–1.22) | 0.843 |
| Income level (ref: low) | ||||||||
| Medium | 1.30 (1.06–1.60) | 0.010 | 1.04 (0.86–1.27) | 0.669 | 0.68 (0.57–0.82) | 0.000 | 0.87 (0.73–1.04) | 0.122 |
| High | 0.83 (0.66–1.05) | 0.116 | 0.88 (0.69–1.11) | 0.269 | 0.93 (0.77–1.13) | 0.467 | 1.10 (0.90–1.34) | 0.355 |
| Country of birth (ref: Sweden) | ||||||||
| Born in Europe (not Sweden) | 1.08 (0.82–1.41) | 0.000 | 0.70 (0.55–0.91) | 0.006 | 0.80 (0.63–1.02) | 0.077 | 0.94 (0.76–1.16) | 0.565 |
| Born outside Europe | 3.43 (2.41–4.89) | 0.000 | 2.79 (1.91–4.09) | 0.000 | 0.78 (0.56–1.09) | 0.148 | 0.70 (0.50–0.97) | 0.030 |
| Grade IV (ref: grade III) | ||||||||
| Grade IV | 0.37 (0.29–0.49) | 0.000 | 0.48 (0.36–0.63) | 0.000 | 0.50 (0.40–0.63) | 0.077 | 0.70 (0.55–0.89) | 0.003 |
Bold values indicate the p value ≤ 0.05
*IRR (CI) = incidence rate ratio with 95% confidence intervals
**Any comorbidity (any comorbidity or no comorbidity according to the Elixhauser definition)